December 2010 Issue of MMM

December 2010 Issue of MMM

December 2010

Editor's Desk

The patently obvious

This time last year, the majority of us were glad to see the back of 2009. The industry welcomed 2010 with an uncertain mix of ...

Features

Outlook 2011: Eye of the Storm

With a wave of mega-blockbusters set to expire in 2011 and with managed care increasingly in the driver's seat, pharmas will get another bite at ...

Outlook 2011: The Uptake Curve

Launching a new pharmaceutical or biologic next year? Expect smaller sales than in years past and a gauntlet of more sophisticated payers, physicians and patients. ...

Pipeline 2011: Launch Prospects

MM&M's Pipeline 2011 offers a short list of the so-called locks and long-shots to reach market over the next months and years. You'll find details ...

Headliner: Boehringer Ingelheim's Wa'el Hashad

In October, Boehringer Ingelheim (BI) won FDA approval for Pradaxa, a blood thinner that reduces stroke risk in patients with non-valvular atrial fibrillation. As the ...

Antidote

Antidote: Coumadin

I and every other clinician who treats patients with the common blood thinner warfarin (Coumadin) have a problem.

In Focus

Coumadin gives lesson for new blood thinners

A love-hate relationship for Coumadin is playing out online, say authors of a new report that may offer lessons for marketers of new blood-thinning products.

Professional Marketing

Sales force triggered Tysabri uptick

Biogen Idec and Elan's MS drug Tysabri realized a 15% increase in US revenues during the third quarter (compared with Q3 2009), a gain at ...

Allergan shifts sales reps to Botox for its new indication

Allergan sales forces previously working on Glaxo-SmithKline headache drugs Imitrex and Amerge as part of a co-promotion will be reassigned to Botox, in support of ...

Professional Marketing briefs

Featuring news about Alcon, SK&A and PLoS Medicine

Med Ed Report

Crowd-sourcing a new med ed model

Pri-Med launched its Open Network, an initiative designed to spur industry-wide innovation in the way professional med ed is developed, delivered and funded.

COI rules might delay drugs: report

In the name of protecting patients, conflict-of-interest (COI) rules imposed by medical schools and public agencies are actually harming them, according to a report from ...

WVU tightens conflict rules

West Virginia University's four health profession schools have adopted new rules governing relations with industry vendors.

Med Ed Report briefs

Featuring news about the NAAMECC (now NAMEC), Lighthouse Learning, Global Education Group and the Alliance for CME

Professional Media

Cancer journal focuses on research

The American Association for Cancer Research (AACR) will launch a new journal--Cancer Discovery--in April 2011.

Pharmacy Times launches specialty

Pharmacy Times launched a new title, Specialty Pharmacy Times, which will focus on policy, regulatory and legal issues, as well as product reviews, reimbursement and ...

Professional Media briefs

Featuring news about Elsevier, the Canadian Cardiovascular Society, the Public Library of Science Medicine and San Lucas Medical Limited

Partner Forum

Will specialty titles start growing?

Publishers of multispecialty and primary care titles enjoyed the largest ad-spend gains in a resurgent first-half 2010. Will things get more interesting for the specialty ...

Digital Media

Online groups are hotbed of promotion

Social networks are a "Wild West" of medical misinformation, a study has found. More than one in four comments on Facebook diabetes communities is promotional ...

MedImmune flu effort has Facebook page, soccer great

MedImmune, together with Women's Professional Soccer and the American Youth Soccer Organization, launched an online campaign promoting flu immunization featuring soccer great Brandi Chastain.

Digital Media briefs

Featuring news about the AMA, WebMD, the AARP and Consumer Reports Health

Consumer Marketing

DDR on DTC: Celebrex

We all know chronic pain is a horrible thing, something people have tried to alleviate with every means possible-- herbal, physical, mystical, even pharmaceutical.

Novo Nordisk launches new campaign for Victoza

Novo Nordisk launched a consumer campaign for Victoza, emphasizing the product's ability to bring down blood sugar levels and body weight in patients with type ...

Bayer settles OTC multivitamin case

Bayer agreed to pay three states $3.3 million to settle charges that it made unsubstantiated claims in advertising that its One A Day Men's multivitamins ...

Marketing Research

Vantage Point

Looking back at the pharmaceutical marketing research professional conferences I have attended in 2010, I am sensing a bit of schizophrenia in the focus of ...

'Meaningful use' for EHRs coming next year

Electronic health records (EHRs) are poised to get a boost from the federal government's "meaningful use" incentive program next year, begging the question: can these ...

Panel firm offers speedy trend analysis

All Global, a Kantar-owned provider of healthcare panel data, has launched a service designed to offer, within 24 hours, analyzed responses to breaking drug news.

Agency Business

PDI acquires digital shop Group DCA

Contract sales giant PDI acquired digital agency Group DCA, seeking to bolster its non-personal promotion capabilities.

DAS buys two international agencies

It's been a busy few weeks for the Adelphi unit of Omnicom's Diversified Agency Services (DAS) as the sub-holding company gobbled up two international agencies.

AbelsonTaylor elevates Drescher

AbelsonTaylor named Nancy Drescher SVP, director of client services, responsible for running the firm's account services department.

Agency Business briefs

Featuring news about GSW Worldwide, Stonefly Communications Group, DDB New York, Tribal DDB New York and Porter Novelli

Washington Insider

As I see it

The FDA's many initiatives on risk management are confusing to the industry--and the problem is, in many ways, of the agency's own making. We need ...

Agency's top side not happy with slow change

FDA commissioner Margaret Hamburg and principal deputy commissioner Joshua Sharfstein say they are concerned by how long it takes to make changes in the agency.

FDA to target CEOs in off-label suits

FDA's chief litigator said he is focusing on corporate chief executives for personal prosecution in cases of flagrant off-label product promotions.

Viewpoint

Mobile rising to become a digital channel leader

As we finish 2010, one of the surprising healthcare marketing headlines has been the rapid ascendancy of mobile as a leading digital channel.

Moving from 'share of voice' to 'share of influence'

Biopharma is caught in a swirl of uncertainty greater than anything it has ever faced: legislative mandates, changing media consumption and patient and professional empowerment.

Back Talk

The vital signs of culture

As our nation continues to debate how the healthcare system should be fixed, little attention has been paid to the need to better incorporate multiculturalism ...

Email Newsletters